Compound 7 and its analogue patented by Gilead Sciences could suppress the proliferation of both trastuzumab-sensitive and trastuzumab-resistant HER2+ BC cells, and reduce tumorigenesis and tumor growth in vivo [122]. Here, ERBB2 is linked to breast cancer.